Hope you are all liking this volatility! Just remember to stay calm, buy real assets and hold for the long-term. If you underwrote and asset at $5 per share and the price falls to $4.50 on zero news, you should be buying more. When Mr. Market pukes on a position you own take the opportunity to load up on a cheaper price.
But before we get into the juice, first a word from today’s sponsor.
Pitch an idea Kevin O’Leary
Do you carry that entrepreneurial spirit? Have you been using it to foster the next big product or idea? Then get ready, because Shark Pitch season is back!
We’re inviting five companies to have the chance to pitch their business LIVE to Kevin O’Leary and the StartEngine community. Founders have the chance to win a $25k grant from Mr. Wonderful himself, with other prizes from our partners!
If you’re the founder of a cool startup, or know a cool startup that would like to pitch a Shark, apply here.
Deadline to apply is October 8th! The competition will be October 15th, at 9am PT/12pm ET.
Disclaimer: Kevin O’Leary is a paid spokesperson for StartEngine. Read the 17-B disclosure: startengine.com/17b
Buy the dip…
That is what I did on movie theater stocks. I made a killing back in 2020 when theater stocks were at basement level lows. No one wanted to own them. They were all trading like their terminal value was zero and cash flows, let alone revenues, would never return.
I didn’t think movie theaters would go out of business so started buying the ones that I thought had the strongest balance sheets. When the Spring of 2021 came along, the stocks peaked. I cashed out and allocated elsewhere.
Prices fluctuated from the Spring to Summer going up and down in a small range. Most investors were expecting the Summer of 2021 to be a banner year as individuals return to the theater amidst a strong box office. Pent-up demand you know?
But as the summer box office slowly approached investors were disappointed as the box office was still down 40-60% compared to the 2019 Summer box office. Theater stocks subsequently fell.
On May 24th, 2021 I decided to start buying back in into my favorite little movie theater company. The stock was trading around $18-19/share. As summer approached the stock continued to fall as the box office was weaker than expected. We had a nice rally in June when the stock went back up to $22/share but after the initial summer burst the stock crumbled. During August and September the stock began to trade below $15 per share.
I was buying all the way down but when it broke under $15 I started to get aggressive. At that point the enterprise value was under $800 million, which was significantly below was the replacement cost of the real estate this company owns is.
In addition, the management team stated on the recent earnings call that they were actively looking to liquidate excess real estate, life insurance polices and had over $24 million in income tax receivables that would turn to cash sometime in the back half. I estimated there could be in excess of $75-100 million in non-core assets turned into cash over the next 12-18 months which would significantly de-risk all operations.
So with an implied enterprise value of $700 million (after all potential asset sales), extremely valuable owned and controlled movie theater and hotel assets and normalized EBITDA in the $100-150 million range, underwriting the security for a 2-3 year time period looked like cake.
I recently wrote an article titled “Top Four Stocks I Own” where I highlighted this little movie theater operator as one of my top positions. This was on September 15th, 2021 when the stock just started to rebound from the summer lows. The stock has continued to run, along with all other movie theater stocks, on the back of a strong box office for the remainder of the year.
In addition, Venom: Let There Be Carnage, performed extremely well this past weekend, bringing in over $90 million in the domestic box office. Remember, this is one of the first movies that Disney has released that does not have same day streaming. More importantly, Disney announced that they are done with the same day streaming model which should incrementally improve the domestic box office on all other films.
There is also a strong slate of movies coming out over the next few months which could catapult the box office back to a more normalized level. The No Time To Die Bond movie should perform extremely well over the coming months given that it is a highly anticipated movie with no same day streaming options.
And even if the box office doesn’t recover back to pre-pandemic levels (which I think is unlikely) I think my favorite little movie theater company will still outperform peers.
Not only does this company outperform their peers almost every quarter, but they have the strongest balance sheet and are one of the only theater companies to own their assets.
Given this large margin of safety, should the domestic box office normalize at a $9-10 billion level, I think this company has a real chance of actually taking market share from over-levered and struggling peers (think AMC).
I am very comfortable holding at the current levels and will continue to average down should Wall Street freak out again about the domestic box office not recovering fast enough. My price target is in the $30/share range which represents significant upside from the current valuation.
Get full access to my research report and join 825 other investors.
Feel free to reach out if you have any questions or would like to see a prior research report. If for any reason you find the service is not for you, reach out to me for a refund before 30 days.
Disclaimer: The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the author or paid advertiser.
Alpha Letter is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.
Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.
The publisher, its affiliates, and clients of the a publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.
Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.
Hi mate, great article, but just wanted to point out that one of the links--"replacement cost of the real estate"-- in the article seems to point to the wrong page/article.
When clicked, it takes you to a page that talks about the importance of speaking with management.
I would be grateful if the link could be fixed. My thanks to you in advance!
Great piece - thank you. I fundamentally agree with your belief in the reopening play but got a little burnt after not locking in gains in certain recovery stocks before Delta took the wind out of their sails. Predicting another variant is tough, but are you at all concerned about the general risk of moving into winter, and the tailwind that provides for the general case load to rise? (Subsequently lowering demand for indoor entertainment like movie theatres?)